Gilead Sciences, Inc.
GILDHealthcare Drug Manufacturers General
Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024.
- Revenue
- +6.83%
- EPS
- −20.2%
- Free cash flow
- +21.1%
- Total debt
- +5.17%
Quarter to September 2026, against a year earlier
Follow GILD
Alert me
Gilead Sciences, Inc. 10-Q filed Oct 30, 2026
What changed
Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Aug 6, 2026: 11 added · 7 removed · 35 modified; 13 with only figures updated; 2 moved without change
-
Added · Virology
•In October 2026, the Centers for Medicare and Medicaid Services completed the process of setting the Maximum Fair Price for Biktarvy under Medicare. The new price will be effective and impact our Biktarvy revenue starting January 1, 2028.